mounjaro semaglutide or tirzepatide more effective in blood sugar control and weight loss than semaglutide, meta-analysis finds Tirzepatide Bests Semaglutide for Real-World

Liver Fibrosis, But No Other Histologic Features, Is Associated With Long-Term Outcomes of Patients With Nonalcoholic Fatty Liver Disease

No peer-reviewed trials support simultaneous administration, and regulatory guidance classifies such use as off-label and potentially unsafe without explicit physician oversight and patient consent

Lu J, Chen L, Liu W, Guo W

Patient subgroups were defined by baseline BMI categories: overweight (BMI 25.0 to 29.9 kg/m 2 ), obesity class 1 (BMI 30.034.9 kg/m 2 ), obesity class 2 (BMI 35.0 to 39.9 kg/m 2 )

Many people begin to see weight changes within three to four weeks, though this varies

The Role of Technology in Tracking Progress and Outcomes Technology is a valuable ally in weight management with GLP-1 therapies